6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
frequently O
occurring O
adverse O
reactions O
( O
> O
= O
5 O
% O
and O
greater O
than O
placebo O
) O
were O
nausea O
, O
headache O
, O
constipation O
, O
dizziness O
, O
insomnia O
, O
hot O
flush O
, O
hyperhidrosis O
, O
vomiting O
, O
palpitations O
, O
heart O
rate O
increased O
, O
dry O
mouth O
, O
and O
hypertension O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Forest O
Laboratories O
, O
LLC. O
, O
at O
( O
800 O
) O
678-1605 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Patient O
Exposure O
Savella O
was O
evaluated O
in O
three O
double-blind O
placebo-controlled O
trials O
involving O
2209 O
fibromyalgia B-Not_AE_Candidate
patients O
( O
1557 O
patients O
treated O
with O
Savella O
and O
652 O
patients O
treated O
with O
placebo O
) O
for O
a O
treatment O
period O
up O
to O
29 O
weeks O
. O

The O
stated O
frequencies O
of O
adverse O
reactions O
represent O
the O
proportion O
of O
individuals O
who O
experienced O
, O
at O
least O
once O
, O
a O
treatment-emergent O
adverse O
reaction O
of O
the O
type O
listed O
. O

A O
reaction O
was O
considered O
treatment O
emergent O
if O
it O
occurred O
for O
the O
first O
time O
or O
worsened O
while O
receiving O
therapy O
following O
baseline O
evaluation O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
In O
placebo-controlled O
trials O
in O
patients O
with O
fibromyalgia B-Not_AE_Candidate
, O
23 O
% O
of O
patients O
treated O
with O
Savella O
100 O
mg/day O
, O
26 O
% O
of O
patients O
treated O
with O
Savella O
200 O
mg/day O
discontinued O
prematurely O
due O
to O
adverse O
reactions O
, O
compared O
to O
12 O
% O
of O
patients O
treated O
with O
placebo O
. O

The O
adverse O
reactions O
that O
led O
to O
withdrawal B-NonOSE_AE
in O
> O
= O
1 O
% O
of O
patients O
in O
the O
Savella O
treatment O
group O
and O
with O
an O
incidence O
rate O
greater O
than O
that O
in O
the O
placebo O
treatment O
group O
were O
nausea B-OSE_Labeled_AE
( O
milnacipran O
6 O
% O
, O
placebo O
1 O
% O
) O
, O
palpitations B-OSE_Labeled_AE
( O
milnacipran O
3 O
% O
, O
placebo O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
milnacipran O
2 O
% O
, O
placebo O
0 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
hyperhidrosis B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
and O
dizziness B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
and O
placebo O
0.5 O
% O
) O
. O

Discontinuation O
due O
to O
adverse O
reactions O
was O
generally O
more O
common O
among O
patients O
treated O
with O
Savella O
200 O
mg/day O
compared O
to O
Savella O
100 O
mg/day O
. O

Most O
Common O
Adverse O
Reactions O
in O
Placebo O
Controlled O
Trials O
In O
the O
placebo-controlled O
fibromyalgia O
patient O
trials O
, O
the O
most O
frequently O
occurring O
adverse O
reaction O
in O
clinical O
trials O
was O
nausea B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
twice O
placebo O
) O
in O
patients O
treated O
with O
Savella O
were O
constipation B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
and O
hypertension B-OSE_Labeled_AE
. O

Table O
4 O
lists O
all O
adverse O
reactions O
that O
occurred O
in O
at O
least O
2 O
% O
of O
patients O
treated O
with O
Savella O
at O
either O
100 O
or O
200 O
mg/day O
and O
at O
an O
incidence O
greater O
than O
that O
of O
placebo O
. O

Table O
4 O
: O
Treatment-Emergent O
Adverse O
Reaction O
Incidence O
in O
Placebo O
Controlled O
Trials O
in O
Fibromyalgia O
Patients O
( O
Events O
Occurring O
in O
at O
Least O
2 O
% O
of O
All O
Savella-Treated O
Patients O
and O
Occurring O
More O
Frequently O
in O
Either O
Savella O
Treatment O
Group O
Than O
in O
the O
Placebo O
Treatment O
Group O
) O
System O
Organ O
Class-Preferred O
Term O
Savella100 O
mg/day O
( O
n O
= O
623 O
) O
% O
Savella200 O
mg/day O
( O
n O
= O
934 O
) O
% O
All O
Savella O
( O
n O
= O
1557 O
) O
% O
Placebo O
( O
n O
= O
652 O
) O
% O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
8 O
7 O
7 O
2 O
Tachycardia B-OSE_Labeled_AE
3 O
2 O
2 O
1 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
1 O
2 O
2 O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
35 O
39 O
37 O
20 O
Constipation B-OSE_Labeled_AE
16 O
15 O
16 O
4 O
Vomiting B-OSE_Labeled_AE
6 O
7 O
7 O
2 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
5 O
5 O
5 O
2 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3 O
3 O
3 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3 O
2 O
2 O
2 O
Chills B-OSE_Labeled_AE
1 O
2 O
2 O
0 O
Chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
2 O
1 O
1 O
1 O
Infections B-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
6 O
6 O
6 O
Investigations B-NonOSE_AE
Heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
5 O
6 O
6 O
1 O
Blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
3 O
3 O
1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
2 O
2 O
0 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
19 O
17 O
18 O
14 O
Dizziness B-OSE_Labeled_AE
11 O
10 O
10 O
6 O
Migraine B-OSE_Labeled_AE
6 O
4 O
5 O
3 O
Paresthesia B-OSE_Labeled_AE
2 O
3 O
2 O
2 O
Tremor B-OSE_Labeled_AE
2 O
2 O
2 O
1 O
Hypoesthesia B-OSE_Labeled_AE
1 O
2 O
1 O
1 O
Tension B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
2 O
1 O
1 O
1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
12 O
12 O
12 O
10 O
Anxiety B-OSE_Labeled_AE
5 O
3 O
4 O
4 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
2 O
2 O
2 O
1 O
Skin B-NonOSE_AE
Disorders I-NonOSE_AE
Hyperhidrosis B-OSE_Labeled_AE
8 O
9 O
9 O
2 O
Rash B-OSE_Labeled_AE
3 O
4 O
3 O
2 O
Pruritus B-OSE_Labeled_AE
3 O
2 O
2 O
2 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
11 O
12 O
12 O
2 O
Hypertension B-OSE_Labeled_AE
7 O
4 O
5 O
2 O
Flushing B-OSE_Labeled_AE
2 O
3 O
3 O
1 O
Weight B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
In O
placebo-controlled O
fibromyalgia O
clinical O
trials O
, O
patients O
treated O
with O
Savella O
for O
up O
to O
3 O
months O
experienced O
a O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
of O
approximately O
0.8 O
kg O
in O
both O
the O
Savella O
100 O
mg/day O
and O
the O
Savella O
200 O
mg/day O
treatment O
groups O
, O
compared O
with O
a O
mean O
weight B-NonOSE_AE
loss I-NonOSE_AE
of O
approximately O
0.2 O
kg O
in O
placebo-treated O
patients O
. O

Genitourinary O
Adverse O
Reactions O
in O
Males O
In O
the O
placebo-controlled O
fibromyalgia B-Not_AE_Candidate
studies O
, O
the O
following O
treatment-emergent O
adverse O
reactions O
related O
to O
the O
genitourinary O
system O
were O
observed O
in O
at O
least O
2 O
% O
of O
male O
patients O
treated O
with O
Savella O
, O
and O
occurred O
at O
a O
rate O
greater O
than O
in O
placebo-treated O
male O
patients O
: O
dysuria B-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
prostatitis B-OSE_Labeled_AE
, O
scrotal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
hesitation I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urethral B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
urine B-OSE_Labeled_AE
flow I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

Other O
Adverse O
Reactions O
Observed O
During O
Clinical O
Trials O
of O
Savella O
in O
Fibromyalgia O
Following O
is O
a O
list O
of O
frequent O
( O
those O
occurring O
on O
one O
or O
more O
occasions O
in O
at O
least O
1/100 O
patients O
) O
treatment-emergent O
adverse O
reactions O
reported O
from O
1824 O
fibromyalgia B-Not_AE_Candidate
patients O
treated O
with O
Savella O
for O
periods O
up O
to O
68 O
weeks O
. O

The O
listing O
does O
not O
include O
those O
events O
already O
listed O
in O
Table O
4 O
, O
those O
events O
for O
which O
a O
drug O
cause O
was O
remote O
, O
those O
events O
which O
were O
so O
general O
as O
to O
be O
uninformative O
, O
and O
those O
events O
reported O
only O
once O
which O
did O
not O
have O
a O
substantial O
probability O
of O
being O
acutely O
life O
threatening O
. O

Adverse O
reactions O
are O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
. O

Adverse O
reactions O
of O
major O
clinical O
importance O
are O
described O
in O
the O
Warnings O
and O
Precautions O
section O
( O
5 O
) O
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
- O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
- O
fatigue B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
Infections B-NonOSE_AE
- O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
- O
contusion B-OSE_Labeled_AE
, O
fall B-OSE_Labeled_AE
Investigations B-NonOSE_AE
- O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
or O
increased O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
- O
hypercholesterolemia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
somnolence B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
- O
depression B-OSE_Labeled_AE
, O
stress B-OSE_Labeled_AE
Skin B-NonOSE_AE
Disorders I-NonOSE_AE
- O
night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
from O
spontaneous O
reports O
of O
Savella O
received O
worldwide O
. O

These O
adverse O
reactions O
have O
been O
chosen O
for O
inclusion O
because O
of O
a O
combination O
of O
seriousness O
, O
frequency O
of O
reporting O
, O
or O
potential O
causal O
connection O
to O
Savella O
. O

However O
, O
because O
these O
adverse O
reactions O
were O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
events O
include O
: O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
- O
supraventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
- O
accommodation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
- O
hyperprolactinemia B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
- O
hepatitis B-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
- O
anorexia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
- O
rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
convulsions B-OSE_Labeled_AE
( O
including O
grand O
mal O
) O
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
Parkinsonism B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
- O
aggression B-OSE_Labeled_AE
, O
anger B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
, O
homicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
- O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
- O
galactorrhea B-OSE_Labeled_AE
Skin B-NonOSE_AE
Disorders I-NonOSE_AE
- O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
- O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE

